Medical Pharmacology Chapter 13: Clinical Use: opioid analgesics in pain management
Anesthetic Premedication with opioids advantageous because of:
Sedative properties
Anxiolytic properties
Analgesic properties
Intraoperative Use and General Uses
Adjuncts to other anesthetics
At high doses: primary anesthetic component
Cardiovascular surgery
Other high-risk surgery (desire to minimize cardiovascular depression)
Intraoperative Use: Regional Administration:
Epidural
Subarachnoid spaces
Long-lasting analgesia:
Catheter inserted into the epidural space
Analgesia following morphine or other strong opioid agonist
Respiratory depression may occur -- requiring naloxone
Common side effects: pruritus, nausea, vomiting-- naloxone reversible
Other Routes of Administration
Rectal suppositories
Epidural: action of the spinal level
Transdermal patch -- systemic effects;
Stable drug plasma levels
Better pain control -- no need for repeated parenteral injections
Fentanyl -- most successful opioid for transdermal use; effective for management to constant pain associated with malignancies
Intranasal: limited use {patients who cannot tolerate oral medication or repeated parenteral drug injections
Patient controlled analgesia (PCA): common use
Patient typically use intravenous injection
Effective in postoperative pain management; less opioid may be used
Potential problems:
Equipment malfunction including improper programming/set up which may lead to improper drug delivery
Tolerance and physical dependence
Clinical appearance: two-three weeks following frequent administration of therapeutic doses
Large doses at short intervals are associated with most rapid tolerance development.
Small doses at long intervals are associated with least rapid tolerance development.
Individuals tolerant to morphine effects are also tolerant to other opioid agonists
Examples:
Meperidine, morphine, methadone, and related compounds exhibit cross-tolerance to:
Analgesic action
Euphoriant effects
Site of actions
Failure to administer drug: leads to withdrawal or abstinence syndrome (significant rebound from pharmacologic opioid effects).
Antagonist-precipitated withdrawal: rapidly developing, powerful abstinence syndrome cause by administration of naloxone or another antagonist
Basis of compulsive use:
Euphoria
Sedation
Indifference to stimuli
Despite the risk of opioid dependence, adequate pain relief should never be withheld just because the opioid has potential for abuse or because of the more complicated prescribing requirements for narcotics.
Prescribing Principles and Guidelines:
Early establishment of therapeutic goals; limits physiologic dependence potential; involve patients in this process
Attempt to limit drug dosage to the established therapeutic level
Particularly for chronic pain management consider alternatives to opioids
Frequently re-evaluate therapeutic needs for opioids use
Way, W.L., Fields, H.L. and Way, E. L. Opioid Analgesics and Antagonists, in Basic and Clinical Pharmacology, (Katzung, B. G., ed) Appleton-Lange, 1998, pp 496-515.
Schuckit, M.A. and Segal D.S., Opioid Drug Abuse and Dependence, In Harrison's Principles of Internal Medicine 14th edition, (Isselbacher, K.J., Braunwald, E., Wilson, J.D., Martin, J.B., Fauci, A.S. and Kasper, D.L., eds) McGraw-Hill, Inc (Health Professions Division), 1998, pp 2508-2512;
Coda, B.A. Opioids, In Clinical Anesthesia, 3rd Edition (Barash, P.G., Cullen, B.F. and Stoelting, R.K.,eds) Lippincott-Ravin Publishers, Philadelphia, New York, 1997, pp 329-358.
DISCLAIMER
|